Posted by Michael Wonder on 13 Jan 2022
JAMP and Alvotech announce Canadian approval of Simlandi, a high concentration biosimilar to Humira, providing access to previously unavailable versions in Canada
10 January 2021 - Health Canada rules that 40 mg/0.4 mL and 80 mg/0.8 mL presentations of Simlandi are not subject to the statutory stay, clearing the way for the launch in the Canadian market.
Alvotech Holdings and JAMP Pharma Group announced today that Health Canada has granted marketing authorisation to JAMP Pharma for a high concentration biosimilar to Humira (adalimumab), developed by Alvotech.
